Organon & Co.
OGN
Classificação em ações
#4354
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Preço da ação
$13.76
Última sincronização: 2026-10-16
Valor de mercado
$3.61B
Variação (1 dia)
-0.04%
Variação (1 ano)
48.28%
País
US
Negociar Organon & Co. (OGN)
Categoria
Healthcare
EPS de Organon & Co. (OGN)
EPS em June 2026 TTM: $0.79
De acordo com os últimos relatórios financeiros e o preço das ações da Organon & Co., o EPS atual da empresa (TTM) é $0.79. No final de 2024, a empresa teve um EPS de $3.36, uma diminuição em relação a ao EPS de 2023, que foi de $4.01.
Histórico de EPS da Organon & Co. de 2017 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $0.79 | 9.72% |
| 2025 | $0.72 | -78.57% |
| 2024 | $3.36 | -16.21% |
| 2023 | $4.01 | 11.08% |
| 2022 | $3.61 | -32.27% |
| 2021 | $5.33 | -37.44% |
| 2020 | $8.52 | -32.97% |
| 2019 | $12.71 | 49.35% |
| 2018 | $8.51 | 19.69% |
| 2017 | $7.11 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $29.89 | 3,683.54% |
US
|
|
| $6.60 | 735.44% |
US
|
|
| $3.55 | 349.37% |
US
|
|
| $1.26 | 59.49% |
US
|
|
| $20.39 | 2,480.89% |
CH
|
